900 reports of this reaction
5.2% of all GEFITINIB reports
#3 most reported adverse reaction
DIARRHOEA is the #3 most commonly reported adverse reaction for GEFITINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 900 FDA adverse event reports linking GEFITINIB to DIARRHOEA. This represents approximately 5.2% of all 17,300 adverse event reports for this drug.
Patients taking GEFITINIB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among GEFITINIB users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for GEFITINIB:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 900 FDA reports for GEFITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 5.2% of all adverse event reports for GEFITINIB, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking GEFITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.